Celgene Makes Executive ChangesBy
In the latest in a series of executive moves, Celgene has appointed David V. Elkins as Executive Vice President (EVP) and Chief Financial Officer (CFO). Elkins will join Celgene on July 1, 2018 and become CFO, effective August 1, 2018. He will succeed current CFO Peter N. Kellogg, who will become Celgene’s EVP and Chief Corporate Strategy Officer until his retirement, planned for mid-2019.
Elkins has more than 25 years of finance, strategy, operations, supply-chain, and business development experience in the US, Europe, and emerging markets. He joins Celgene from Johnson & Johnson (J&J), where he was Worldwide Vice President and CFO for consumer products, medical devices, and corporate functions. Prior to his leadership role at J&J, Elkins was CFO for Round Rock Research, a technology-investigation and patent-licensing company. From 2008 to 2012, Elkins was EVP and CFO of Becton, Dickinson and Company, a medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca. He began his career in finance at The Boeing Company in 1991.
Kellogg joined Celgene as CFO in August 2014. In his new role of Chief Corporate Strategy Officer, Kellogg will work with the executive team to define Celgene’s strategy for long-term, sustainable growth beyond 2020. Kellogg will also work with Elkins to ensure the transition of all financial and operational matters. Both Kellogg and Elkins will report directly to Celgene’s Chairman and Chief Executive Officer, Mark J. Alles, as well as serve on Celgene’s Executive Committee.
Celgene announced in April 2018 that Scott A. Smith, President and Chief Operating Officer (COO), was leaving the company. His primary responsibilities have been assumed by Alles.